cc-401
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2005 (NCT00126893)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- c-Jun N-terminal kinase 1INHIBITOR
MAPK8 inhibitor
- c-Jun N-terminal kinase 3INHIBITOR
MAPK10 inhibitor
- c-Jun N-terminal kinase 2INHIBITOR
MAPK9 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4nnc[nH]4)cc23)c1- Mol. weight
- 388.48 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1614713 ↗
Also known as
- cc 401
- cc-401
- cc-401
- cc-401
- cc-401
- cc-401
- cc401 cpd
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00126893 | Phase 1 | Oct 1, 2005 | Celgene |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celgene | For profit | 1 | 1 | 1 | 2005 |
1 organizations
Page 1 / 1